Lowenstein Sandler represented Relmada Therapeutics, Inc. in an exclusive licensing agreement with Trigone Pharma, Ltd. for NDV-01, a clinical stage product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC). NDV-01 is currently undergoing a Phase 2, Single-Arm study to test safety and efficacy in patients with NMIBC, for which Relmada will assume responsibility.
The licensing terms includes a $3.5 million upfront payment and the issuance by Relmada of 10 percent of its outstanding shares to Trigone, as well as up to $200 million in development and commercial milestones and a three percent (3%) royalty on any net sales pending successful commercialization. Relmada receives exclusive worldwide rights to NDV-01 with the exception of Israel, India, and South Africa.
Relmada intends to assess other strategic product opportunities to leverage its extensive development resources.
Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations.
Trigone Pharma Ltd. is a privately held specialty pharmaceutical company focused on the development of a proprietary sustained-release platform designed to enhance the efficacy and safety of established therapeutic agents for urologic diseases into the urinary bladder with clear unmet medical needs.
The Lowenstein team included Michael J. Lerner, Nicholas G. Mehler, and Daniel C. Porco.
